Hsa_circ_0092887 targeting <scp>miR</scp>‐490‐5p/<scp>UBE2T</scp> promotes paclitaxel resistance in non‐small cell lung cancer

Wang, Limei; Zhang, Zhiyong; Tian, Hui

doi:10.1002/jcla.24781

Cited by 8 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, treating tumors such as NSCLC is becoming difficult because chemotherapeutic drugs are ineffective due to resistance. It was found that the hsa_circ_0092887-mediated miR-490-5p/UBE2T signaling axis may contribute to paclitaxel-resistance intervention in NSCLC (111).…”

Section: Cancer Therapies Involving Ube2tmentioning

confidence: 99%

Diverse roles of UBE2T in cancer (Review)

Yan

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

As a leading cause of mortalities worldwide, cancer results from accumulation of both genetic and epigenetic alterations. Disruption of epigenetic regulation in cancer, particularly aberrant ubiquitination, has drawn increasing interest in recent years. The present study aimed to review the roles of ubiquitin-conjugating enzyme E2 T (UBE2T) and its associated pathways in the pathogenesis of pan-cancer, and the development of small-molecule modulators to regulate ubiquitination for treatment strategies. The current study comprehensively investigated the expression landscape and functional significance of UBE2T, as well as its correlation with cancer cell sensitivity to chemotherapy/radiotherapy. Multiple levels of evidence suggested that aberrant UBE2T played important roles in pan-cancer. Information was collected from 16 clinical trials on ubiquitin enzymes, and it was found that these molecules had an important role in the ubiquitin-proteasome system. Further studies are necessary to explore their feasibility and effectiveness as diagnostic and prognostic biomarkers, or as up/down-stream and therapeutic targets for cancer treatment.

show abstract

Section: Cancer Therapies Involving Ube2tmentioning

confidence: 99%

Diverse roles of UBE2T in cancer (Review)

Yan

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Circ_0092887 inhibiting decreased cell growth and migration, while increased apoptosis in NSCLC cells treated with PTX. Circ_0092887 regulated the PTX resistance via miR-490-5p/UBE2T axis in NSCLC [ 129 ]. Matrix metalloproteinases (MMPs) are the key enzymes that break down extracellular matrix (ECM) and collagen to promote tumor angiogenesis and metastasis [ 130 ].…”

Section: Introductionmentioning

confidence: 99%

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells

Maharati

Moghbeli

2023

Cell Div

View full text Add to dashboard Cite

Lung cancer as the leading cause of cancer related mortality is always one of the main global health challenges. Despite the recent progresses in therapeutic methods, the mortality rate is still significantly high among lung cancer patients. A wide range of therapeutic methods including chemotherapy, radiotherapy, and surgery are used to treat lung cancer. Doxorubicin (DOX) and Paclitaxel (TXL) are widely used as the first-line chemotherapeutic drugs in lung cancer. However, there is a significant high percentage of DOX/TXL resistance in lung cancer patients, which leads to tumor recurrence and metastasis. Considering, the side effects of these drugs in normal tissues, it is required to clarify the molecular mechanisms of DOX/TXL resistance to introduce the efficient prognostic and therapeutic markers in lung cancer. MicroRNAs (miRNAs) have key roles in regulation of different pathophysiological processes including cell division, apoptosis, migration, and drug resistance. MiRNA deregulations are widely associated with chemo resistance in various cancers. Therefore, considering the importance of miRNAs in chemotherapy response, in the present review, we discussed the role of miRNAs in regulation of DOX/TXL response in lung cancer patients. It has been reported that miRNAs mainly induced DOX/TXL sensitivity in lung tumor cells by the regulation of signaling pathways, autophagy, transcription factors, and apoptosis. This review can be an effective step in introducing miRNAs as the non-invasive prognostic markers to predict DOX/TXL response in lung cancer patients.

show abstract

Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer

Wang

Zhang

Tian

2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Chemoresistance is a major contributing factor to cancer treatment failure. Emerging research reveals that circular RNA (circRNA) dysregulation is implicated in chemoresistance. Our current study aimed to investigate the involvement of hsa_circ_0092887 in paclitaxel (PTX) resistance in non‐small cell lung cancer (NSCLC). Methods RT‐qPCR as well as western blotting were used for the analysis of hsa_circ_0092887, miR‐490‐5p and UBE2T expression in PTX‐resistant NSCLC tumor tissues and cells. CCK‐8 assay was done to determine the IC50 value of PTX. CCK‐8 assay, wound healing assay, analysis of apoptosis related proteins (Bax and Bcl‐2), and xenograft mouse models were utilized to investigate the role of hsa_circ_0092887 in PTX‐resistance in NSCLC. The binding sites of miR‐490‐5p to hsa_circ_0092887 or UBE2T were predicted by bioinformatics tools and were verified by RIP and dual‐luciferase assays. Results Expression of hsa_Circ_0092887 was upregulated in NSCLC tumor samples/cell lines, and its expression was also higher in PTX‐resistant tumor samples/cell lines when compared with their respective controls. Silencing of hsa_circ_0092887 in PTX‐treated NSCLC cells inhibited cell proliferation and migration, induced apoptosis, and suppressed tumor growth in xenograft mouse models in vivo. MiR‐490‐5p was a direct target of hsa_circ_0092887, and UBE2T was a functional downstream target of hsa_circ_0092887/miR‐490‐5p axis. Hsa_circ_0092887 depletion‐induced anti‐cancer effects in PTX‐treated NSCLC cells were reversed by miR‐490‐5p inhibitor. Furthermore, inhibition of miR‐490‐5p strengthened UBE2T expression, thereby attenuating the anti‐cancer effects caused by UBE2T knockdown. Conclusion Hsa_circ_0092887 depletion alleviated PTX‐resistance in NSCLC cells via modulating the miR‐490‐5p/UBE2T axis, and the targeted management of hsa_circ_0092887‐mediated signaling axis might contribute to PTX‐resistance intervention in NSCLC.

show abstract

Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer

Cited by 8 publications

References 36 publications

Diverse roles of UBE2T in cancer (Review)

Diverse roles of UBE2T in cancer (Review)

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells

Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer

Contact Info

Product

Resources

About